The PI3K/Akt/mTOR pathway has become an important therapeutic target for SCLC [48,50] because several studies have shown that its inhibition results in reduced growth, promotion of apoptosis and enhanced sensitivity to cisplatin/etoposide in both SCLC cells and PDX models [50,51,52]. This evidence concerns the gene AKT1 and small cell lung carcinoma.